July 29, 2025 – Today, Robert F. Kennedy Jr. held a press conference addressing the growing concerns surrounding kratom and its derivatives, particularly focusing on the rise of synthetic compounds like 7-hydroxymitragynine (7-OH).
At Spectrum Kratom, we stand firmly with the U.S. Food and Drug Administration (FDA) in their efforts to regulate and clean up the kratom marketplace to ensure consumer safety. As a company committed to providing the highest quality, all-natural kratom leaf products, we believe this is a pivotal moment for the industry and for the millions of Americans who rely on kratom for its natural benefits.
The Press Conference: A Call for Regulation and Safety
During the press conference, RFK Jr. highlighted the need for responsible oversight in the kratom industry, echoing concerns raised by the FDA and advocates like the American Kratom Association (AKA). The discussion centered on the dangers posed by synthetic and chemically manipulated products, such as those containing high levels of 7-OH, which are often marketed misleadingly as “kratom.” These products, sold in forms like gummies, tablets, and drinkable shots, have raised alarms due to their potent opioid-like effects and lack of regulatory oversight.
The FDA’s recent actions, including issuing warning letters to companies illegally marketing 7-OH products, were a key focus of the conference. RFK Jr. emphasized the importance of distinguishing between natural kratom leaf products and these synthetic derivatives, which can pose significant health risks. He also called for stronger federal and state regulations to protect consumers while preserving access to safe, natural kratom. This aligns with the AKA’s push for Kratom Consumer Protection Acts (KCPAs), which set standards like limiting 7-OH content to no more than 2% of total alkaloids (less than 1 mg per serving).
Spectrum Kratom’s Commitment to Quality and Safety
At Spectrum Kratom, we wholeheartedly support the FDA’s crackdown on dangerous, chemically manipulated products. Our mission has always been to provide pure, unadulterated kratom leaf products that meet the highest standards of quality and safety. We believe that the proliferation of synthetic 7-OH products not only endangers consumers but also threatens the reputation and legal status of natural kratom.Our commitment to excellence includes:
- Sourcing Only Natural Kratom Leaf: We work directly with trusted farmers in Southeast Asia to ensure our products are derived from pure Mitragyna speciosa leaves, free from synthetic additives or enhancements.
- Rigorous Testing: Every batch of our kratom is tested by independent third-party labs to verify purity, alkaloid content, and the absence of contaminants like heavy metals or bacteria.
- Transparent Labeling: We provide clear, accurate information about our products, including recommended serving sizes and alkaloid profiles, empowering consumers to make informed choices.
- Advocacy for Regulation: We support initiatives like the KCPA, which promote responsible manufacturing practices and protect consumers from misbranded or adulterated products.
Why We Stand with the FDA
The FDA’s recent warning letters to seven companies marketing 7-OH products highlight the urgent need to address bad actors in the kratom marketplace. These products, often sold as dietary supplements or unapproved drugs, make unsubstantiated claims about treating conditions like pain, anxiety, or opioid withdrawal. As the FDA has stated, kratom is not lawfully marketed as a drug, dietary supplement, or food additive in the U.S., and synthetic compounds like 7-OH have not been proven safe or effective for any use.We agree with the FDA’s stance that these products pose significant risks, including addiction, liver toxicity, and even death in rare cases when combined with other substances. By cracking down on these dangerous formulations, the FDA is taking a critical step toward protecting consumers and ensuring that only safe, natural kratom products remain available.
The Path Forward: A Safer Kratom Marketplace
At Spectrum Kratom, we see today’s press conference as a call to action for the entire industry. The unregulated proliferation of synthetic kratom derivatives has created confusion and risk for consumers, while also undermining the potential benefits of natural kratom. We urge all vendors and retailers to stop selling 7-OH products and to adopt responsible practices that prioritize consumer safety.We also encourage consumers to be vigilant:
- Check Product Labels: Avoid products listing high concentrations of 7-OH (above 1 mg per serving) or those marketed with exaggerated claims of euphoria or opioid-like effects.
- Demand Transparency: Only purchase from vendors who provide certificates of analysis from reputable labs.
- Support Regulation: Learn about and advocate for state-level KCPAs to ensure a safer marketplace.
Our Vision for the Future
As a leader in the kratom industry, Spectrum Kratom is dedicated to working with regulators, advocates, and consumers to create a marketplace where natural kratom can thrive safely and responsibly. We believe that kratom, when produced and consumed responsibly, offers a natural alternative for millions of Americans seeking wellness and balance. By aligning with the FDA’s efforts to eliminate dangerous synthetic products, we hope to preserve access to high-quality, natural kratom while protecting the health and trust of our customers.Today’s press conference marks a turning point for the kratom industry, and Spectrum Kratom is proud to stand on the side of safety, transparency, and quality. Together, we can build a marketplace that honors the traditional use of kratom while embracing modern standards of consumer protection.For more information about safe kratom use and our products, visit [Spectrum Kratom’s website] or learn about the Kratom Consumer Protection Act at [KratomAnswers.org].
Sources:
- The Washington Post, “FDA to announce crackdown on synthetic substance derived from kratom,” July 29, 2025
- Reuters, “American Kratom Association Applauds FDA Crackdown on Dangerous Chemically Manipulated 7-OH, Pseudoindoxyl and ‘M’ Products,” July 1, 2025
- FDA, “FDA and Kratom,” July 15, 2025
- Reuters, “National Consumer Alert on 7-OH Products Posing Significant Dangers,” July 18, 2025
Disclaimer: This blog reflects Spectrum Kratom’s perspective and commitment to quality. Always consult with a healthcare professional before using kratom or any wellness product.